Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerhard Gründer

Showing results (1-10 of 213) with videos related to

Pageof 22
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|June 24, 2010
Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depressionGerhard Gründer
Pharmacopsychiatry|June 25, 2021
Psychedelics: A New Treatment Paradigm in Psychiatry?Gerhard Gründer
Pharmacopsychiatry|September 20, 2017
Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in NeuropsychopharmacologyGerhard Gründer
Der Nervenarzt|April 3, 2020
[Digital phenotyping. Contra]Gerhard Gründer
Neuroimage|December 2, 2008
"Absolute" or "relative": choosing the right outcome measure in neuroimagingGerhard Gründer
Psychopharmacology|July 27, 2002
Prolactin secretion is not a core dimension of "atypicality"Gerhard Gründer, Otto Benkert
The New England Journal of Medicine|August 26, 2021
Psilocybin for DepressionGerhard Gründer, Lea Mertens
The International Journal of Neuropsychopharmacology|September 1, 2006
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazoleMichael Paulzen, Gerhard Gründer
Journal of Neurochemistry|January 18, 2021
Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT<sub>2A</sub> receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease" on page 658Gerhard Gründer, Paul Cumming
Der Nervenarzt|March 3, 2025
[Between efficacy and criticism: antidepressants in discourse]Gerhard Gründer, Michael Bauer
Pageof 22

Showing results (1-10 of 213) with videos related to

Sort By:
Pageof 22
Current Opinion in Investigational Drugs (London, England : 2000)|June 24, 2010
Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depressionGerhard Gründer
Pharmacopsychiatry|June 25, 2021
Psychedelics: A New Treatment Paradigm in Psychiatry?Gerhard Gründer
Pharmacopsychiatry|September 20, 2017
Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in NeuropsychopharmacologyGerhard Gründer
Der Nervenarzt|April 3, 2020
[Digital phenotyping. Contra]Gerhard Gründer
Neuroimage|December 2, 2008
"Absolute" or "relative": choosing the right outcome measure in neuroimagingGerhard Gründer
Psychopharmacology|July 27, 2002
Prolactin secretion is not a core dimension of "atypicality"Gerhard Gründer, Otto Benkert
The New England Journal of Medicine|August 26, 2021
Psilocybin for DepressionGerhard Gründer, Lea Mertens
The International Journal of Neuropsychopharmacology|September 1, 2006
Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazoleMichael Paulzen, Gerhard Gründer
Journal of Neurochemistry|January 18, 2021
Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT<sub>2A</sub> receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease" on page 658Gerhard Gründer, Paul Cumming
Der Nervenarzt|March 3, 2025
[Between efficacy and criticism: antidepressants in discourse]Gerhard Gründer, Michael Bauer
Pageof 22